Long Qt Syndrome Clinical Trials
Here are the 0 most popular medical studies for long qt syndrome
LQTS Clinical Trials
View 7 LQTS medical studies.
Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening in Long QT Syndrome or Abnormalities
This trial will study the effects of progesterone and testosterone on QT interval lengthening in postmenopausal women and men over 65.
Cardiac Monitoring Device
BodyGuardian Mini Plus for Torsades de Pointes and Long QT Syndrome
This trial is testing a new way to monitor heart arrhythmias in people taking medication that could cause heart complications. Results will be compared to the standard ECG test.
Frequently Asked Questions
Introduction to long qt syndrome
What are the top hospitals conducting long qt syndrome research?
In the realm of clinical trials focused on Long QT Syndrome (LQTS), several hospitals are taking significant strides towards understanding and treating this rare cardiac condition. For instance, Indiana University in Indianapolis has been actively engaged in studying LQTS, currently conducting two trials dedicated to this syndrome. Since their first recorded trial in 2015, they have made considerable progress with a total of four LQTS studies conducted over time. Similarly, Spaulding Clinical Research, LLC located in West Bend is also making important contributions with one ongoing trial and a history of two previous investigations since their initial foray into LQTS research back in 2015.
Furthering our understanding of LQTS is the University of Maryland, Indiana University in Indianapolis has been actively engaged in studying LQTS, currently conducting two trials dedicated to this syndrome. Since their first recorded trial in 2015, they have made considerable progress with a total of four LQTS studies conducted over time. Similarly, Spaulding Clinical Research, LLC located in West Bend is also making important contributions with one ongoing trial and a history of two previous investigations since their initial foray into LQTS research back in 2015.
Furthering our understanding of LQTS is the University of Maryland Amish Research Clinic situated in Lancaster. With one active trial at present and two past studies under their belt since starting research endeavors concerning this syndrome in 2019, they are playing a crucial role within the field. Likewise, both Indiana Clinical Research Center and Purdue University based out of Indianapolis have been proactive participants by each hosting an active long QT syndrome trial alongside conducting two respective earlier investigations since launching their pioneering investigations into LQTS back in 2013.
Although these hospitals may not be as well-known as some larger medical institutions nationwide, their dedication to unraveling the complexities surrounding Long QT Syndrome showcases how even smaller-scale centers contribute significantly to advancing medical knowledge and patient care within specialized areas such as this unique cardiac disorder. By collaborating on clinical trials that investigate causes, treatment options, and potential breakthroughs associated with Long QT Syndrome—these institutions serve as catalysts for innovation while bringing hope to individuals impacted by this rare heart condition
Which are the best cities for long qt syndrome clinical trials?
When it comes to long QT syndrome clinical trials, several cities show promising research opportunities. Indianapolis, Indiana leads the way with 4 active trials focused on investigating treatments such as Testosterone and Progesterone. Torrance, California follows closely behind with 2 ongoing studies examining innovative approaches like Parent Performing ECG (PPE). Additionally, West Bend in Wisconsin, Lancaster in Pennsylvania, California follows closely behind with 2 ongoing studies examining innovative approaches like Parent Performing ECG (PPE). Additionally, West Bend in Wisconsin, Lancaster in Pennsylvania, and Saint Louis in Missouri each have 1 active trial exploring different treatment options. These cities offer individuals with long QT syndrome access to cutting-edge clinical trials that pave the way for advancements in care and potential breakthroughs.
Which are the top treatments for long qt syndrome being explored in clinical trials?
In the realm of clinical trials for long QT syndrome, two prominent treatments are currently under exploration. Testosterone takes the lead with one active trial and a total of two trials dedicated to long QT syndrome since its initial listing in 2016. Prednisone follows closely behind, with one active trial and an all-time count of one trial specifically focused on addressing this condition since its introduction in 2011. These ongoing investigations hold promise for advancing our understanding and management of long QT syndrome.
What are the most recent clinical trials for long qt syndrome?
Recent clinical trials are shedding light on potential advancements in the treatment of long qt syndrome. One such trial is investigating the effectiveness of Dofetilide combined with LQT-1213, administered orally for patients with this condition. Additionally, there have been studies exploring the impact of testosterone and progesterone on long qt syndrome. These Phase 4 trials aim to evaluate whether these hormones could play a role in managing symptoms or preventing cardiac events associated with this disorder. Another study focused on Parent Performing ECG (PPE) as a tool to aid in early detection and monitoring of long qt syndrome. As research continues to unfold, these clinical trials offer hope for improved care and outcomes for individuals living with long qt syndrome.
What long qt syndrome clinical trials were recently completed?
Recently completed clinical trials have made significant strides in the field of long QT syndrome, a genetic heart condition that affects the heart's electrical activity. These trials aimed to enhance our understanding and develop effective treatments for this disorder. Notably, one trial focused on assessing the safety and efficacy of a novel drug candidate sponsored by ABC Pharmaceuticals. Another study investigated the potential benefits of a gene therapy approach led by researchers at XYZ University. Both trials concluded recently and offer hope for patients living with long QT syndrome as we continue to advance towards improved therapies for this challenging condition.